Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy
New Delhi: Novavax, Inc.today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in…